Related Experiment Videos
Clinical gene therapy for nonmalignant disease
Thomas A Ratko1, Joseph P Cummings, John Blebea
1Clinical Knowledge Services, University HealthSystem Consortium, Oak Brook, Illinois 60523-1890, USA. ratko@uhc.edu
The American Journal of Medicine
|November 6, 2003
Summary
Gene therapy shows limited evidence of benefit for genetic disorders like cystic fibrosis and hemophilia. Further research is crucial as no Phase 3 trials confirm clinical efficacy for gene therapy applications.
Area of Science:
- Biotechnology
- Medical Genetics
- Clinical Research
Background:
- Gene therapy offers potential definitive treatment for genetic diseases.
- Current gene therapy approaches aim for targeted genetic material transfer and expression.
Purpose of the Study:
- To review clinical gene therapy trials for various disorders.
- To assess the current evidence for gene therapy's clinical benefits.
Main Methods:
- Systematic review of clinical gene therapy trials.
- Analysis of trials for nonmalignant, single-gene, multifactorial, and infectious diseases.
Main Results:
- Limited evidence suggests potential benefits for severe combined immunodeficiency, cystic fibrosis, coronary/peripheral arterial disease, and hemophilia.
- No Phase 3 randomized controlled trials have been completed to confirm efficacy.
- Difficulty in correlating clinical benefits with gene therapy administration.
Conclusions:
- Additional clinical and basic research is necessary.
- The future role of gene therapy requires further investigation to establish definitive clinical benefits.